Cancer DiscoveryImmunologyPeer-reviewed journal article
An immunomechanical checkpoint PYK2 governs monocyte-to-macrophage differentiation in pancreatic cancer
Wenyan XieiD, Xin YuiD, Qingxin YangiD, Nengwen KeiD, Ping WangiD, Hao KongiD, Xiangji WuiD, Panpan MaiD, Lang CheniD, Jie YangiD, Xiuqin FengiD, Yuan WangiD, Hubing ShiiD, Lu CheniD, Yunhua LiuiD, Bi‐Sen DingiD, Qiang WeiiD, Hong JiangiD
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a fibrotic, stiff tumor microenvironment (TME), where tumor-associated macrophages (TAMs) drive ECM remodeling, progression, and immune evasion. The contribution of mechanical cues to monocyte differentiation into TAMs remains largely unexplored. Here we show that mechanical force is required for monocyte-to-macrophage differentiation. PYK2, as an innovative immunomechanical checkpoint, de facto governs this differentiation process. We demonstrated that PYK2 senses mechanical signals via Piezo1 and integrins, triggering F-actin polymerization and translocating to the nucleus to regulate mechanotransduction and differentiation genes (e.g., ACTR3, RELA). Targeted deletion of PYK2 impairs the differentiation and polarization of monocyte-derived macrophages, reshapes the PDAC microenvironment, and enhances the efficacy of anti-PD-1 immunotherapy. These findings underscore the critical role of mechanical cues in monocyte differentiation and suggest that targeting PYK2 is a promising strategy to modulate TAM function and improve immunotherapy outcomes in patients with PDAC. Statement of significanceThis study identifies PYK2 as an immunomechanical checkpoint that drives monocyte-to-macrophage differentiation in PDAC via Piezo1/integrin-mediated mechanical cues. Targeted deletion of PYK2 reshapes the PDAC microenvironment, and enhances the efficacy of anti-PD-1 immunotherapy, suggesting PYK2 as a promising therapeutic target to overcome immunotherapy resistance.
- organism: mouse
- assay: proteomics
- assay: imaging
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- research focus: cell type annotation
- approach: experimental assay
- approach: mechanistic / dynamical model
- Citations
- 47
- FWCI
- 15.97
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Macrophage proliferation machinery leads to PDAC progression, but susceptibility to innate immunotherapy.
D. G. DeNardo, C. Zuo, … J. D. Weber·bioRxiv·Nov 8, 2021
- Tumor-specific CD4 T cells instruct monocyte differentiation in pancreatic ductal adenocarcinoma
M. T. Patterson, A. L. Burrack, … I. M. Stromnes·bioRxiv·Nov 9, 2022
- Notch signaling regulates immunosuppressive tumor-associated macrophage function in pancreatic cancer
W. Yan, N. G. Steele, … F. Bednar·bioRxiv·Jan 11, 2023
- A macrophage-derived noncanonical WNT niche drives immune exclusion in pancreatic cancer
Na Hyun Kim, Young Min Song, … Yi Rang Na·bioRxiv·Feb 9, 2026
- Targeting Siglec-10/α3β1 Integrin Interactions Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Pratima Saini, Gauri Mirji, … Mohamed Abdel‐Mohsen·Cancer ResearchPeer-reviewed·Nov 3, 2025
- MAP Kinase inhibition reshapes tumor microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages
P. Delfino, C. Neander, … V. Corbo·bioRxiv·Sep 8, 2019